This is the way.

치매 치료 예방

Treatment Method and Therapeutics

www.cell.com/iscience/fulltext/S2589-0042(22)00544-2

Dapsone is an anticatalysis for Alzheimer’s disease exacerbation

경도인지장애와 치매, 알츠하이머병 치료기

이종훈. 경도인지장애와 치매, 알츠하이머병 치료기. INFOMEDPRESS, 2022. https://books.google.co.kr/books?id=m3ZjEAAAQBAJ.

답손 치료는 알츠하이머병에서 발생하는 인터페론 과다 생산을 억제하는 항촉매 반응을 사용합니다: 연구논문발표 Infomed Press. INFOMEDPRESS, 2022. https://books.google.co.kr/books?id=yeJwEAAAQBAJ.

Experimental Proof is published.

Concerted type I interferon signaling in microglia and neural cells promotes memory impairment associated with amyloid β plaques

DOI:https://doi.org/10.1016/j.immuni.2022.03.018

The gut microbiota prime systemic antiviral immunity via the cGAS-STING-IFN-I axis

DOI:https://doi.org/10.1016/j.immuni.2022.04.006i022.04.006

치매관리법과 과학 치매증상개선제의 위험성

치매증상개선제는 사망자수를 증가시킵니다.

프랑스를 중심으로 치매증상개선제의 처방은 대폭 감소하고 있습니다.

Ben Hassen, Céline, Rameen Tahir, Archana Singh-Manoux, Dejan Milic, Claire Paquet, Séverine Sabia, and Julien Dumurgier. 2022. "Ten-Year Trends in Sales of Alzheimer Disease Drugs in France Compared With Sales in Germany, Spain, and the UK." JAMA Health Forum 3 (8): e222253-e222253. https://doi.org/10.1001/jamahealthforum.2022.2253.

독일과 스페인도 치매증상개선제의 처방은 감소하였습니다.

한국은 치매증상개선제의 처방이 네 배 증가하였고 처방횟수도 증가하였습니다. 그리고 치매증상개선제 복용자 중 사망자수가 증가한다는 사실이 발표 되었습니다.

The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea

The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea - Naunyn-Schmiedeberg's Archives of PharmacologyThe Dementia Management Act (DMA) came into effect on August 4, 2011, in South Korea. Diagnosis and medication were rapidly performed for dementia in a short time. We investigated the cardiac effects of increased drug prescription following DMA. We observed a correlation between Alzheimer’s disease (AD) and anti-AD drug (AAD) groups from 2010 to 2019 on the National Health Insurance System (NHIS) of South Korea. This study investigated the increase and decrease in deaths of AD patients with AAD. We analysed the mortality per 100,000 population with the R2 Calculator. Moreover, we made the up or down datum line for the simple decision on the listed, delisted, and sustainable drug examined by a linear equation and R2. We observed that life expectancy was diminished by AAD in Sorokdo National Hospital. In the NHIS, donepezil and rivastigmine increased the number of deaths decided on R2 > 0.75. Memantine was sustainable. We could not decide on galantamine because it is one of the other groups. We made a straightforward decision-maker of delisted, listed, or sustainable criteria based on mortality and datum line.

Recovery of Dementia Syndrome following Treatment of Brain Inflammation - PubMedThis finding means that dementia syndrome is an inflammatory disease. This research suggests that diagnostic criteria for Alzheimer's disease should be based on the presence or absence of inflammation in neurons. Because inflammation in neurons can occur in middle age due to various causes, we can t …

The Neuroinflammasome in Alzheimer's Disease and Cerebral Stroke - PubMedAAD can occasionally exacerbate AD and stroke. DDS can alleviate mild cognitive impairment (MCI), early AD and stroke. We clinically confirmed the role of DDS as a neuroinflammasome competitor after stroke. DDS preserved neuronal survival within 24-55 h in the Seoul Study cohort.